Drug intelligence / Profile preview

ISX9-CPC

Development stage: Preclinical
Lead developer: IPS HEART
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intracoronary, Intramyocardial

Overview

ISX9-CPC is a patented, induced pluripotent stem cell (iPSC)-derived cardiac progenitor cell (CPC) therapy developed by IPS HEART for the treatment of heart failure and rare cardiomyopathies, including Duchenne and Danon Cardiomyopathy. The therapy is produced by using the small molecule ISX-9 (isoxazole 9) to direct the differentiation of iPSCs into functional CPCs. Once administered, these cells are intended to regenerate functional human heart muscle and reduce cardiac fibrosis by replacing scar tissue with new, contractile myocardium. The program has completed a Pre-IND meeting with the FDA and has been granted multiple Rare Pediatric Drug Designations for its target indications.

Other names: ISX9-CPCISX-9-CPCISX 9-CPC

Beyond the preview

Go deeper on ISX9-CPC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISX9-CPC.

Explore the full profile